Application

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected p14ARF in HeLa, A431, and NIH 3T3 cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected p14ARF in human testis tissue sections.Affinity Binding Assay: A representative lot of this antibody bound human recombinant p14ARF with a KD of 2.0 x 10-7 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-p14ARF, clone 4F19 ZooMAb, Cat. No. ZRB1581, is a recombinant Rabbit monoclonal antibody that specifically targets p14ARF and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry, and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

GST/His-tagged full-length human recombinant Tumor suppressor ARF

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 4F19 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects p14ARF.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Tumor suppressor ARF (UniProt: Q8N726; also known as Alternative reading frame, ARF, Cyclin-dependent kinase inhibitor 2A, p14ARF) is encoded by the CDKN2A (also known as CDKN2, MLM) gene (Gene ID: 1029) in human. p14ARF serves as a tumor suppressor and is a key regulator of cellular proliferation. It is shown to be frequently inactivated in human cancers. It binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhances p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis by preventing the activation of cyclin B1/CDC2 complexes. It can form a ternary complex with p120(E4F) and p53 to enhance p14ARF-induced G2 cell cycle arrest in a p53-dependent manner. p14ARF also binds to E2F1 and MYC and blocks their transcriptional activator activity without affecting MYC transcriptional repression. Human p14ARF is shown to promote the proteasomal degradation of Melanoma antigen-A11 (MAGE-A11) independent of HDM2 E3 ubiquitin ligase or lysine ubiquitination. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Minges, JT et al. (2015). J. Biol. Chem. 290, 25174-25187. Rizos, H., et al. (2003). J. Biol. Chem. 278, 4981-4989).